Shares of BridgeBio Pharma, Inc. (BBIO) rose on Thursday morning after the company reported positive Phase 3 topline results for its oral therapy infigratinib for achondroplasia.
The stock is currently trading at $79.94, up $6.61 or 9.02%, on the Nasdaq. The stock opened at $84.85 after closing Monday at $73.33. The stock has traded between $28.33 and $84.94 in the past 52-week period.
BridgeBio said its phase 3 trial met its primary endpoint, showing statistically significant improvement in annualized height velocity compared to placebo in children with achondroplasia. The therapy also demonstrated the first statistically significant improvement in body proportionality reported in a randomized trial for the condition.
The company plans to meet with regulators to discuss submissions for U.S. and European approval in the second half of 2026.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.